2026跨国药企大湾区行座谈会在广州举行

Core Viewpoint - The Greater Bay Area (GBA) is positioning itself as a strategic hub for global pharmaceutical innovation, with significant discussions among multinational pharmaceutical companies and local government officials aimed at enhancing the region's healthcare ecosystem [1][2]. Group 1: Policy and Development Initiatives - Guangdong has introduced nearly 20 policy documents in the past two years to create a comprehensive development plan for the pharmaceutical industry, focusing on sustainable growth and innovation [2]. - The GBA is recognized for its vast market potential and improving innovation ecosystem, making it a strategic location for future development by multinational pharmaceutical companies [2]. - The establishment of a regular mechanism for publishing innovative drug and medical device product catalogs aims to expedite the inclusion of more innovative drugs into the medical insurance directory [2]. Group 2: Insurance and Payment Systems - Guangdong has initiated a system allowing personal medical insurance accounts to purchase commercial health insurance, with 10 cities implementing this and 22 pilot hospitals offering direct payment options [2]. - A one-stop settlement service combining medical insurance and commercial insurance has been introduced to further alleviate patient financial burdens [2]. Group 3: Regulatory and Approval Processes - The "Hong Kong-Macao Medical Device and Drug Access" policy has significantly improved approval efficiency, with the number of approved products increasing from 48 in 2023 to 146 currently [4]. - The number of designated medical institutions for these products has expanded from 19 to 71, covering nine cities in the GBA [4]. Group 4: Real-World Research and Collaboration - The GBA is seen as an ideal location for conducting real-world research, with several multinational companies establishing production bases or regional headquarters in Guangdong [5]. - There are ongoing collaborations between multinational pharmaceutical companies and local medical institutions to conduct real-world studies, with seven companies partnering with four institutions on nine projects [4][5]. Group 5: Future Directions and Recommendations - Suggestions have been made for Guangdong to establish a provincial commercial insurance innovative drug settlement platform to streamline processes and reduce operational costs for insurance companies [3]. - There is a call for specific incentive measures to encourage medical institutions to expedite the implementation of commercial insurance [3].